NUE insider sale: Kenneth Query disposes 10,000 shares at ~$145
Rhea-AI Filing Summary
Nucor Corporation (NUE) Form 4: Executive Vice President Kenneth Rex Query reported the sale of 10,000 shares of Nucor common stock on 08/18/2025 at a weighted average price of $144.902, with transaction prices ranging from $144.735 to $145.050. After the sale, the reporting person beneficially owned 84,080 shares, held directly. The filing lists no derivative transactions. The Form 4 was signed on behalf of Mr. Query by attorney-in-fact Caitlin A. Kelly on 08/20/2025, and includes an explanatory footnote that the reported price is a weighted average from multiple sales.
Positive
- Full disclosure provided of weighted average price and price range for the sale
- Post-transaction beneficial ownership is reported (84,080 shares), improving transparency
- No derivatives reported, simplifying interpretation of the reporting person's exposure
Negative
- Insider sale of 10,000 shares may be perceived negatively by some investors despite no further context
- No indication in this filing that the sale was made pursuant to a 10b5-1 plan
Insights
TL;DR: Insider sale of 10,000 shares reduces direct holdings to 84,080; transaction appears routine with full price disclosure.
The sale of 10,000 shares at a weighted average of $144.902 represents a clear, disclosed disposition by an executive officer rather than a derivative exercise or company action. The filing provides the price range and states the weighted average methodology, enabling precise auditability. Because no additional transactions or derivative positions are reported, this appears to be a straightforward sale and not part of a reported 10b5-1 plan in this filing.
TL;DR: Disclosure is complete on face of Form 4; sale is a typical insider disposition with no derivatives reported.
The Form 4 properly identifies the reporting person, role (Executive Vice President), and post-transaction beneficial ownership, and includes an explanatory footnote about the weighted average price. The signature by an attorney-in-fact is noted. There is no indication in this filing of any irregularity, planned-sale designation, or change in control implications.